GLP-1R agonists reduce body weight, decrease glycemia, and reduce the development of cardiovascular disease, establishing this mechanism as foundational for future development of new more effective therapies for cardiometabolic disorders. How to make the next generation therapies even more effective? Here we discuss the emerging field of peptide multi-agonists, highlight promising scientific mechanisms and therapeutic approaches for the treatment of diabetes and associated comorbidities